SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022)
16 references·0 citing·35 second hop
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022) (2025)Benchmarking R&D success rates of leading…2021 FDA approvals (2022)2021 FDA approvals2020 FDA drug approvals (2021)2020 FDA drug approvals2019 FDA drug approvals (2020)2019 FDA drug approvals2018 FDA drug approvals (2019)2018 FDA drug approvals2016 FDA drug approvals (2017)2016 FDA drug approvalsTrends in clinical success rates (2016)Trends in clinical success ra…Parsing clinical success rates (2016)Parsing clinical success rates2014 FDA drug approvals (2015)2014 FDA drug approvalsClinical development success rates for investigational drugs (2014)Clinical development success …2012 FDA drug approvals (2013)2012 FDA drug approvalsDiagnosing the decline in pharmaceutical R&D efficiency (2012)Diagnosing the decline in pha…2011 FDA drug approvals (2012)2011 FDA drug approvalsHow to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…2009 FDA drug approvals (2010)2009 FDA drug approvals2008 FDA drug approvals (2009)2008 FDA drug approvalsEconomics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)The price of innovation: new estimates of drug development costs (2003)Can the pharmaceutical industry reduce attrition rates? (2004)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)A Comprehensive Map of FDA-Approved Pharmaceutical Products (2018)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Lessons from 60 years of pharmaceutical innovation (2009)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Are Ideas Getting Harder to Find? (2020)Generating Theory by Abduction (2021)Cost of innovation in the pharmaceutical industry (1991)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Incentives for orphan drug research and development in the United States (2008)The High Cost of Cancer Drugs and What We Can Do About It (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Forecasting drug utilization and expenditure in a metropolitan health region (2010)Opening the door to innovation (2014)National trends in prescription drug expenditures and projections for 2020 (2020)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures (2017)Approval success rates of drug candidates based on target, action, modality, application, and their combinations (2021)Open innovation in neuroscience research and drug discovery (2018)Many are called, few are chosen: the role of science in drug development decisions (2023)Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis (2025)The predicated demise of racemic new molecular entities is an exaggeration (2012)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)Two Decades of Publishing Excellence in Pharmaceutical Biotechnology (2014)2018 FDA Tides Harvest (2019)The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules (2019)The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules (2020)Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action (2021)The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules (2022)Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023)
this work references cited by second hop

References

  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,686 cited
  • 2014Clinical development success rates for investigational drugs2,616 cited
  • 2012Diagnosing the decline in pharmaceutical R&D efficiency2,039 cited
  • 2007Economics of New Oncology Drug Development348 cited
  • 2016Trends in clinical success rates277 cited
  • 20192018 FDA drug approvals213 cited
  • 20092008 FDA drug approvals191 cited
  • 20212020 FDA drug approvals186 cited
  • 2016Parsing clinical success rates167 cited
  • 20122011 FDA drug approvals156 cited
  • 20202019 FDA drug approvals150 cited
  • 20132012 FDA drug approvals132 cited
  • 20222021 FDA approvals124 cited
  • 20172016 FDA drug approvals122 cited
  • 20152014 FDA drug approvals113 cited
  • 20102009 FDA drug approvals98 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work